Clinical trial
A Phase 1, Open-label Study to Evaluate the Single Dose Pharmacokinetics of Telotristat Etiprate in Male and Female Subjects With Mild, Moderate and Severe Hepatic Impairment and Matched Subjects With Normal Hepatic Function
NCT02683577 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-label Study to Evaluate the Single Dose Pharmacokinetics of Telotristat Etiprate in Male and Female Subjects With Mild, Moderate and Severe Hepatic Impairment and Matched Subjects With Normal Hepatic Function
- Lead sponsor
- Ipsen
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 29, 2016
- Completion date
- July 31, 2016
- Enrollment
- 24 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
hepatic impairment